BioCentury | Mar 2, 2017
Finance

Drugging RNA

With a tranched $38 million series A round led by Canaan Partners , Arrakis Therapeutics Inc. is putting an initial set of hits into preclinical development, and building out a platform that will allow it to...
BioCentury | Apr 4, 2016
Finance

Medicxi's platform exception

Medicxi Ventures spurned its typical asset-centric model for the second time this month because the firm thought Gadeta B.V .'s T cell receptor platform was too good an opportunity to pass up. On March 29,...
BioCentury | Mar 14, 2016
Finance

Medicxi's antibody experiment

Medicxi Ventures ' first investment since spinning out from Index Ventures is likely to be an outlier for the firm. Rather than pursuing its primary path of being the sole investor that plucks a single...
BioCentury | Mar 14, 2016
Financial News

Capella Bioscience completes venture financing

Capella Bioscience Ltd. , London, U.K. Business: Cancer, Autoimmune Date completed: 2016-03-08 Type: Venture financing Raised: L11 million ($15.6 million) Investors: Advent Life Sciences; Medicxi Ventures; Osage University Partners WIR Staff autoimmune cancer...
BioCentury | Mar 9, 2016
Financial News

Capella raises L11 million series A

Capella Bioscience Ltd. (London, U.K.) raised L11 million ($15.6 million) in a tranched series A round with Advent Life Sciences, Medicxi Ventures and Osage University Partners. Capella's lead program is a first-in-class antibody that inhibits...
Items per page:
1 - 5 of 5
BioCentury | Mar 2, 2017
Finance

Drugging RNA

With a tranched $38 million series A round led by Canaan Partners , Arrakis Therapeutics Inc. is putting an initial set of hits into preclinical development, and building out a platform that will allow it to...
BioCentury | Apr 4, 2016
Finance

Medicxi's platform exception

Medicxi Ventures spurned its typical asset-centric model for the second time this month because the firm thought Gadeta B.V .'s T cell receptor platform was too good an opportunity to pass up. On March 29,...
BioCentury | Mar 14, 2016
Finance

Medicxi's antibody experiment

Medicxi Ventures ' first investment since spinning out from Index Ventures is likely to be an outlier for the firm. Rather than pursuing its primary path of being the sole investor that plucks a single...
BioCentury | Mar 14, 2016
Financial News

Capella Bioscience completes venture financing

Capella Bioscience Ltd. , London, U.K. Business: Cancer, Autoimmune Date completed: 2016-03-08 Type: Venture financing Raised: L11 million ($15.6 million) Investors: Advent Life Sciences; Medicxi Ventures; Osage University Partners WIR Staff autoimmune cancer...
BioCentury | Mar 9, 2016
Financial News

Capella raises L11 million series A

Capella Bioscience Ltd. (London, U.K.) raised L11 million ($15.6 million) in a tranched series A round with Advent Life Sciences, Medicxi Ventures and Osage University Partners. Capella's lead program is a first-in-class antibody that inhibits...
Items per page:
1 - 5 of 5